Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 4
2017 2
2018 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.
van der Heijden LC, Kok MM, Zocca P, Sen H, Löwik MM, Mariani S, de Man FHAF, Hartmann M, Stoel MG, van Houwelingen KG, Louwerenburg JHW, Linssen GCM, Doggen CJM, Grandjean JG, von Birgelen C. van der Heijden LC, et al. Among authors: louwerenburg jhw. J Am Heart Assoc. 2018 Jan 30;7(3):e007212. doi: 10.1161/JAHA.117.007212. J Am Heart Assoc. 2018. PMID: 29382666 Free PMC article.
Although newer generation drug-eluting stents showed favorable short-term safety profiles, there is a lack of long-term outcome data. ...
Although newer generation drug-eluting stents showed favorable short-term safety profiles, there is a lack of long-term outcom …
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C. Zocca P, et al. Among authors: louwerenburg jhw. JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031. JACC Cardiovasc Interv. 2018. PMID: 29519378 Free article. Clinical Trial.
1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
Chandrasekhar J, Kok MM, Kalkman DN, Aquino MB, Zocca P, Woudstra P, Beijk MA, Kerkmeijer LS, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Pocock S, von Birgelen C, Mehran R, de Winter RJ; COMBO Collaborators and BIO-RESORT Investigators. Chandrasekhar J, et al. JACC Cardiovasc Interv. 2020 Apr 13;13(7):820-830. doi: 10.1016/j.jcin.2019.11.023. JACC Cardiovasc Interv. 2020. PMID: 32273094 Free article.
(Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population [BIO-RESORT], NCT01674803; MASCOT-Post Marketing Registry [MASCOT], NCT02183454; Prospective Registry to Assess the Long-term Safety and Performance of the Combo Stent …
(Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population [BIO-RESORT], NCT01674803; MASCOT-P …
Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG, van der Heijden LC, Lam MK, Kok MM, Löwik MM, Louwerenburg JW, Linssen GC, IJzerman MJ, Doggen CJ, von Birgelen C. van Houwelingen KG, et al. Among authors: louwerenburg jw. Heart Vessels. 2016 Nov;31(11):1731-1739. doi: 10.1007/s00380-015-0786-6. Epub 2016 Jan 8. Heart Vessels. 2016. PMID: 26747438 Free PMC article. Clinical Trial.
TBLs are characterized by the obstruction of both main vessel and side-branch. Limited data are available on long-term clinical outcome following TBL treatment with newer-generation DES. ...Patients were categorized into TBL (Medina classes: 1.1.1; 1.0.1; 0.1.1) versus non …
TBLs are characterized by the obstruction of both main vessel and side-branch. Limited data are available on long-term clinical outco …
Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial.
Hoedemaker NPG, Damman P, Woudstra P, Hirsch A, Windhausen F, Tijssen JGP, de Winter RJ; ICTUS Investigators. Hoedemaker NPG, et al. J Am Coll Cardiol. 2017 Apr 18;69(15):1883-1893. doi: 10.1016/j.jacc.2017.02.023. J Am Coll Cardiol. 2017. PMID: 28408018 Free article. Clinical Trial.
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T. …
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a …
Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG, Sen H, Lam MK, Tandjung K, Löwik MM, de Man FH, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GC, Doggen CJ, von Birgelen C. van Houwelingen KG, et al. Among authors: louwerenburg jh. Catheter Cardiovasc Interv. 2015 Feb 15;85(3):E76-82. doi: 10.1002/ccd.25713. Epub 2014 Nov 1. Catheter Cardiovasc Interv. 2015. PMID: 25339110 Clinical Trial.
OBJECTIVE: To compare long-term outcome of patients treated for chronic total occlusion (CTO) lesions versus patients treated for non-CTO lesions only. BACKGROUND: Percutaneous coronary interventions (PCI) for CTO lesions generally have a higher adverse event risk than PCI …
OBJECTIVE: To compare long-term outcome of patients treated for chronic total occlusion (CTO) lesions versus patients treated for non …
Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS.
Huisman J, van der Heijden LC, Kok MM, Louwerenburg JH, Danse PW, Jessurun GA, de Man FH, Löwik MM, Linssen GC, IJzerman MJ, Doggen CJ, von Birgelen C. Huisman J, et al. Among authors: louwerenburg jh. J Cardiol. 2017 Apr;69(4):660-665. doi: 10.1016/j.jjcc.2016.06.010. Epub 2016 Jul 28. J Cardiol. 2017. PMID: 27476343 Free article.
BACKGROUND: Data on medium-term outcome of patients with acute coronary syndrome (ACS), treated with newer-generation durable polymer drug-eluting stents (DES) in severely calcified coronary lesions, are scarce. ...
BACKGROUND: Data on medium-term outcome of patients with acute coronary syndrome (ACS), treated with newer-generation durable polymer …
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K, Sen H, Lam MK, Basalus MWZ, Louwerenburg JHW, Stoel MG, van Houwelingen KG, de Man FHAF, Linssen GCM, Saïd SAM, Nienhuis MB, Löwik MM, Verhorst PMJ, van der Palen J, von Birgelen C. Tandjung K, et al. Among authors: louwerenburg jhw. J Am Coll Cardiol. 2013 Jun 18;61(24):2406-2416. doi: 10.1016/j.jacc.2013.04.005. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602769 Free article. Clinical Trial.
., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months. BACKGROUND: Only limited long-term follow-up data are available from hea …
., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict disconti …
Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study.
Kok MM, von Birgelen C, Lam MK, Löwik MM, van Houwelingen KG, Stoel MG, Louwerenburg JH, de Man FH, Hartmann M, Doggen CJ, van Til JA, IJzerman MJ. Kok MM, et al. Among authors: louwerenburg jh. EuroIntervention. 2016 Apr 20;11(13):1487-94. doi: 10.4244/EIJY15M10_06. EuroIntervention. 2016. PMID: 26465376 Free article.
AIMS: To keep patients in long-term clinical follow-up programmes after percutaneous coronary intervention (PCI), knowledge of the patient-preferred mode for follow-up assessment is crucial. ...
AIMS: To keep patients in long-term clinical follow-up programmes after percutaneous coronary intervention (PCI), knowledge of the pa …
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM. von Birgelen C, et al. Among authors: louwerenburg jhw. Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30. Lancet. 2016. PMID: 27806902 Clinical Trial.
Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, oft …
Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term …